目的　探讨基因工程肿瘤细胞融合疫苗的抗肿瘤作用。方法　将鼠源性IL 12 (mIL 12 )基因转染J5 5 8细胞制备工程瘤细胞 ,再与树突状细胞进行融合后免疫BALB c小鼠 ,14d后再以不同剂量的瘤细胞攻击小鼠以观察其保护效力。结果　制备的工程瘤细胞J5 5 8经测试其培养上清中mIL 12表达量为 (870± 6 0 )pg·(10 5细胞 ) - 1 ·ml- 1 ;与树突状细胞体外融合后 ,镜下测得细胞融合率约为 30 % ;收集免疫小鼠腹股沟及月国窝淋巴结细胞与肿瘤细胞共培养 ,其上清IFN γ含量较对照组高 ;体内、外特异性抗肿瘤实验均显示该型瘤苗具有良好的抗瘤作用。结论　免疫小鼠体内诱导Th1应答 ,其明显的抗肿瘤功效为临床应用提供了可能性 Objective To investigate the antitumor effect of genetically engineered tumor cell fusion vaccine. Methods The murine IL-12 (mIL 12) gene was transfected into J5 5 8 cells to construct tumor cells. After fusion with dendritic cells, BALB / c mice were immunized. After 14 days, mice were challenged with different doses of tumor cells To observe its protective effect. Results The constructed tumor cells J5 5 8 were cultured in the culture supernatant and the expression level of mIL 12 was (870 ± 60) pg · (10 5 cells) -1 · ml -1. After fusion with dendritic cells in vitro, The cell fusion rate measured by microscope was about 30%. The immunized mice inoculated with the groin and the lymph node of the lymph node were co-cultured with the tumor cells, and the IFNγ content in the supernatant was higher than that in the control group. Both in vitro and in vivo anti-tumor experiments This type of tumor vaccine has a good anti-tumor effect. Conclusion The induction of Th1 response in immunized mice and its obvious antitumor efficacy provide the possibility of clinical application